---
title: "In the performance report, CLOUDR's annual loss widened to 924 million yuan"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/280715321.md"
description: "CLOUDR announced its full-year results for the year ended December last year, with a revenue of RMB 1.623 billion, a year-on-year decrease of 53.5%. The loss widened to RMB 924 million, compared to a loss of RMB 516 million in the same period last year; the loss per share was RMB 1.52. No dividend was declared"
datetime: "2026-03-27T01:50:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280715321.md)
  - [en](https://longbridge.com/en/news/280715321.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280715321.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/280715321.md) | [繁體中文](https://longbridge.com/zh-HK/news/280715321.md)


# In the performance report, CLOUDR's annual loss widened to 924 million yuan

CLOUDR (09955.HK) announced its full-year results for the year ended last December, with revenue of RMB 1.623 billion, a year-on-year decrease of 53.5%. Losses widened to RMB 924 million, compared to a loss of RMB 516 million in the same period last year; loss per share was RMB 1.52. No dividend was declared

### 相关股票

- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-CN/quote/159929.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md)
- [CLOUDR (09955.HK)](https://longbridge.com/zh-CN/quote/09955.HK.md)
- [Dacheng CSI All Share Health Care Equipment and Services ETF (516610.CN)](https://longbridge.com/zh-CN/quote/516610.CN.md)

## 相关资讯与研究

- [Seres Group Refines AGM Agenda With Detailed Share Buyback Resolutions](https://longbridge.com/zh-CN/news/281431575.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-CN/news/281343251.md)
- [In pursuit of profit, India Inc slows R&D as innovation takes back seat](https://longbridge.com/zh-CN/news/281098039.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-CN/news/281501537.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-CN/news/281035304.md)